Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy

• Published in: Journal of the American Society of Nephrology Vol. 27; no. 11; pp. 3459 - 3468
• Main Authors: Scheele, Wim, Diamond, Susan, Gale, Jeremy, Clerin, Valerie, Tamimi, Nihad, Le, Vu, Walley, Rosalind, Grover-Páez, Fernando, Perros-Huguet, Christelle, Rolph, Timothy, El Nahas, Meguid
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.11.2016
• Subjects: Adult; Aged; Aged, 80 and over; Albuminuria - drug therapy; Albuminuria - enzymology; Albuminuria - etiology; Clinical Research; Diabetic Nephropathies - complications; Double-Blind Method; Female; Heterocyclic Compounds, 2-Ring - therapeutic use; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors - therapeutic use; Sulfonamides - therapeutic use; albuminuria; nitric oxide; randomized controlled trials; diabetic nephropathy

Diabetic nephropathy (DN) is the leading cause of ESRD worldwide. Reduced bioavailability or uncoupling of nitric oxide in the kidney, leading to decreased intracellular levels of the nitric oxide pathway effector molecule cyclic guanosine monophosphate (cGMP), has been implicated in the progression...